FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis | MicrobiomeTrials← Back to trialsNCT06801665
FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-04-17Est. Completion: 2027-02-01
Enrollment target: 30 participants Locations- The Second People's Hospital of Changzhou, Changzhou, China
Other microbiome trials you might be interested in
Colorectal NeoplasmsLiver NeoplasmsNeoplasm MetastasesColorectal Liver MetastasesMetastatic Colorectal Cancer (CRC)
Patients whose colorectal cancer has spread to the liver, and whose liver metastases cannot be removed by surgery or des…
Berlin, GermanyEst. completion Mar 31, 2036
Colorectal NeoplasmsNeoplasmsIntrahepatic CholangiocarcinomaAdrenocortical Carcinoma
Metastasis, Neoplasm
Background:
Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors …
Bethesda, United StatesEst. completion Dec 31, 2029